Program
Fulvestrant
Also written as “PF-07104091 + PF-07220060 + fulvestrant dose expansion”, “fulvestrant” and “faslodex 500mg”.
Its studies are mostly in Breast Neoplasms · Neoplasms · Carcinoma, Intraductal, Noninfiltrating · Puberty, Precocious · Endometrial Neoplasms, led by 5 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 211 open or running | phase 4since May 4, 2015 | Jul 21, 2003 | none ahead |
| Atossa Therapeutics | 10 open or running | phase 2since Aug 28, 2015 | Aug 28, 2015 | none ahead |
| Criterium | 11 open or running | phase 2since Sep 3, 2020 | Sep 3, 2020 | Dec 31, 2027phase 2 · NCT04567420 |
| Eagle Pharmaceuticals | 10 open or running | phase 1since Oct 24, 2017 | Oct 24, 2017 | none ahead |
| Fresenius Kabi | 10 open or running | phase 1since May 30, 2016 | May 30, 2016 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 11 studies since Jul 21, 2003.
- Apr 10, 2006Phase 2 study in Breast NeoplasmsAstraZeneca · NCT00313170 · 144 enrolled · Belgium, Canada, Czechia and more
- May 18, 2006Phase 1 study in Advanced Breast CancerAstraZeneca · NCT00328120 · 20 enrolled · Japan
- May 18, 2006Phase 3 study in Advanced Breast CancerAstraZeneca · NCT00327769 · 234 enrolled · China
- Jun 5, 2006Phase 2 study in Endometrial NeoplasmsAstraZeneca · NCT00334295 · 35 enrolled · Germany
- Jul 20, 2006Phase 2 study in Breast NeoplasmsAstraZeneca · NCT00357110 · 13 enrolled · Austria, Germany, Norway
- Mar 7, 2008Phase 3 study in Advanced Breast CancerAstraZeneca · NCT00635713 · 588 enrolled
- Jul 22, 2009Phase 3 study in Breast NeoplasmsAstraZeneca · NCT00944918 · 25 enrolled · Korea, Republic of
- Feb 17, 2011Phase 3 study in Breast NeoplasmsAstraZeneca · NCT01300351 · 249 enrolled · China
- May 11, 2012Phase 3 study in NeoplasmsAstraZeneca · NCT01602380 · 462 enrolled · United States, Argentina, Brazil and more
- May 4, 2015Phase 4 study in Breast NeoplasmsAstraZeneca · NCT02447328 · 83 enrolled · Korea, Republic of
- Aug 28, 2015Atossa Therapeutics's first study: phase 2 study in Female Breast CarcinomaNew to Atossa TherapeuticsAtossa Therapeutics · NCT02540330 · 3 enrolled · United States
- May 30, 2016Fresenius Kabi's first study: phase 1 study in HealthyNew to Fresenius KabiFresenius Kabi · NCT02795039 · 266 enrolled · Canada
- Oct 24, 2017Eagle Pharmaceuticals's first study: phase 1 study in PharmacokineticsNew to Eagle PharmaceuticalsEagle Pharmaceuticals · NCT03324061 · 600 enrolled · United States
- Sep 3, 2020Criterium's first study: phase 2 study in Breast NeoplasmsNew to CriteriumCriterium · NCT04567420 · 70 enrolled · United States
Ahead
- Dec 31, 2027Primary completion: phase 2 study in Breast NeoplasmsCriterium · NCT04567420
TargetBeta
“Estrogen receptor alpha antagonist; Estrogen receptor degrader”ChEMBL 37, by rule
Other programs on ESR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Ethinyl Estradiolrule | Johnson & Johnson | phase 4 | 70 |
| Estradiolrule | Novo Nordisk | phase 4 | 69 |
| Tamoxifenrule | AstraZeneca | phase 4 | 21 |
| Clomiphenerule | Hamad Medical | phase 4 | 3 |
| vepdegestrantrule | Pfizer | phase 3 | 20 |
| camizestrantrule | AstraZeneca | phase 3 | 18 |
| giredestrant | Hoffmann-La Roche | phase 3 | 17 |
| HRS-8080 | Jiangsu HengRui Medicine | phase 3 | 13 |
| elacestrantrule | Menarini Group | phase 3 | 12 |
| Imlunestrantrule | Eli Lilly | phase 3 | 12 |
| taragarestrantrule | InventisBio | phase 3 | 5 |
| SIM0270rule | Simcere Pharmaceutical Group | phase 3 | 5 |
Studies
All 25 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT04567420Breast Neoplasms · United States | 2 | Active, not recruiting | Criterium | Dec 31, 2027 | 70 |
| NCT03324061Pharmacokinetics · United States | 1 | Completed | Eagle Pharmaceuticals | Jul 12, 2018 | 600 |
| NCT02795039Healthy · Canada | 1 | Completed | Fresenius Kabi | Mar 3, 2017 | 266 |
| NCT02540330Female Breast Carcinoma · United States | 2 | Terminated | Atossa Therapeutics | Aug 13, 2020 | 3 |
| NCT02447328Breast Neoplasms · Korea, Republic of | 4 | Completed | AstraZeneca | May 6, 2016 | 83 |
| NCT01602380Neoplasms · United States, Argentina, Brazil and more | 3 | Completed | AstraZeneca | Apr 11, 2016 | 462 |
| NCT01300351Breast Neoplasms · China | 3 | Completed | AstraZeneca | Mar 2014 | 249 |
| NCT00944918Breast Neoplasms · Korea, Republic of | 3 | Completed | AstraZeneca | Jun 2011 | 25 |
| NCT00635713Advanced Breast Cancer | 3 | Completed | AstraZeneca | 588 | |
| NCT00357110Breast Neoplasms · Austria, Germany, Norway | 2 | Completed | AstraZeneca | Oct 2008 | 13 |
| NCT00334295Endometrial Neoplasms · Germany | 2 | Completed | AstraZeneca | Jan 2011 | 35 |
| NCT00328120Advanced Breast Cancer · Japan | 1 | Completed | AstraZeneca | Apr 2006 | 20 |
| NCT00327769Advanced Breast Cancer · China | 3 | Completed | AstraZeneca | 234 | |
| NCT00313170Breast Neoplasms · Belgium, Canada, Czechia and more | 2 | Completed | AstraZeneca | Jun 13, 2008 | 144 |
| NCT00305448Breast Neoplasms · Japan | 2 | Completed | AstraZeneca | Mar 2008 | 143 |
| NCT00278915Puberty, Precocious · United States, France, Germany and more | 2 | Completed | AstraZeneca | Dec 8, 2009 | 30 |
| NCT00274469Breast Neoplasms · United States, Brazil, Bulgaria and more | 2 | Completed | AstraZeneca | Jan 10, 2008 | 205 |
| NCT00272740Breast Neoplasms · Belgium, Switzerland | 2 | Completed | AstraZeneca | 93 | |
| NCT00259090Breast Neoplasms · United Kingdom | 2 | Completed | AstraZeneca | Oct 2008 | 120 |
| NCT00256698Breast Neoplasms · Canada, Costa Rica, Finland and more | 3 | Completed | AstraZeneca | Apr 2009 | 514 |
| NCT00241449Breast Neoplasms · United States, Argentina, Australia and more | 3 | Completed | AstraZeneca | Mar 2007 | 51 |
| NCT00234403Breast Neoplasms · Spain | 2 | Completed | AstraZeneca | 60 | |
| NCT00099437Breast Neoplasms · United States, Belgium, Brazil and more | 3 | Active, not recruiting | AstraZeneca | Feb 27, 2009 | 736 |
| NCT00093002Breast Neoplasms · United States, Austria, Brazil and more | 2 | Completed | AstraZeneca | 179 | |
| NCT00065325Breast Neoplasms · United States, Argentina, Belgium and more | 3 | Completed | AstraZeneca | Jun 2006 | 694 |
How it is read
Names in the registry
- “Fulvestrant”, 26 entries
- “PF-07104091 + PF-07220060 + fulvestrant dose expansion”, 2 entries
- “fulvestrant”, 2 entries
- “faslodex 500mg”, 1 entry
- “Fulvestrant injection”, 1 entry
Conditions, from the studies’ own filings
- Breast Neoplasms, 23 studies
- Neoplasms, 1 study
- Carcinoma, Intraductal, Noninfiltrating, 1 study
- Puberty, Precocious, 1 study
- Endometrial Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.